表紙:ブレヤンジ医薬品の考察と市場予測 - 2032年
市場調査レポート
商品コード
1397400

ブレヤンジ医薬品の考察と市場予測 - 2032年

BREYANZI Drug Insight and Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
ブレヤンジ医薬品の考察と市場予測 - 2032年
出版日: 2023年12月19日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、主要7市場(米国、ドイツ、フランス、イタリア、スペイン、英国、日本)におけるブレヤンジについて調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 DLBCLにおけるブレヤンジの概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • 規制上のマイルストーン
  • その他の開発活動
  • 製品のプロファイル

第3章 競合情勢(上市済みの治療法)

第4章 競合情勢(後期の新治療法)

第5章 ブレヤンジ市場の評価

  • DLBCLにおけるブレヤンジの市場見通し
  • 主要7市場の分析
    • 主要7市場のDLBCL向けブレヤンジの市場規模
  • 市場の分析:国別
    • 米国のDLBCL向けブレヤンジの市場規模
    • ドイツのDLBCL向けブレヤンジの市場規模
    • 英国のDLBCL向けブレヤンジの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: BREYANZI, Clinical Trial Description, 2023
  • Table 2: BREYANZI, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: BREYANZI Market Size in the 7MM, in USD million (2019-2032)
  • Table 6: BREYANZI Market Size in the US, in USD million (2019-2032)
  • Table 7: BREYANZI Market Size in Germany, in USD million (2019-2032)
  • Table 8: BREYANZI Market Size in France, in USD million (2019-2032)
  • Table 9: BREYANZI Market Size in Italy, in USD million (2019-2032)
  • Table 10: BREYANZI Market Size in Spain, in USD million (2019-2032)
  • Table 11: BREYANZI Market Size in the UK, in USD million (2019-2032)
  • Table 12: BREYANZI Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: BREYANZI Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: BREYANZI Market Size in the United States, USD million (2019-2032)
  • Figure 3: BREYANZI Market Size in Germany, USD million (2019-2032)
  • Figure 4: BREYANZI Market Size in France, USD million (2019-2032)
  • Figure 5: BREYANZI Market Size in Italy, USD million (2019-2032)
  • Figure 6: BREYANZI Market Size in Spain, USD million (2019-2032)
  • Figure 7: BREYANZI Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: BREYANZI Market Size in Japan, USD million (2019-2032)
目次
Product Code: DIDM1173

"BREYANZI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about BREYANZI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the BREYANZI for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the BREYANZI for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BREYANZI market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

BREYANZI (Lisocabtagene maraleucel) is an investigational CAR-T-cell therapy designed to target CD19, a surface glycoprotein expressed during normal B-cell development. Liso-cel CAR-T-cells aim to target and kill non-Hodgkin lymphoma cells through a CAR construct that includes an anti-CD19 single-chain variable fragment (scFv) targeting domain for antigen specificity, a transmembrane domain, a 4-1BB costimulatory domain hypothesized to increase T-cell proliferation and persistence, and a CD3-zeta T-cell activation domain. The defined composition of liso-cel CAR-positive viable T cells consisting of CD8 and CD4 components may reduce product variability; however, the clinical significance of the defined composition is unknown. Liso-cel was initially developed by Juno Therapeutics; later, Celgene acquired the company in 2018; in 2019, Celgene was acquired by Bristol Myers Squibb.

As per the company 2022, recent corporate presentation, BREYANZI is a best-in-class anti-CD19 with the broadest US 2L LBCL label, and the company anticipates continuing capacity expansion in 2023.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the BREYANZI description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
  • Elaborated details on BREYANZI regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the BREYANZI research and development activities in DLBCL across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around BREYANZI.
  • The report contains forecasted sales of BREYANZI for DLBCL till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for DLBCL.
  • The report also features the SWOT analysis with analyst views for BREYANZI in DLBCL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BREYANZI Analytical Perspective by DelveInsight

In-depth BREYANZI Market Assessment

This report provides a detailed market assessment of BREYANZI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

BREYANZI Clinical Assessment

The report provides the clinical trials information of BREYANZI for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BREYANZI dominance.
  • Other emerging products for DLBCL are expected to give tough market competition to BREYANZI and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BREYANZI in DLBCL.
  • Our in-depth analysis of the forecasted sales data of BREYANZI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BREYANZI in DLBCL.

Key Questions:

  • What is the product type, route of administration and mechanism of action of BREYANZI?
  • What is the clinical trial status of the study related to BREYANZI in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BREYANZI development?
  • What are the key designations that have been granted to BREYANZI for DLBCL?
  • What is the forecasted market scenario of BREYANZI for DLBCL?
  • What are the forecasted sales of BREYANZI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to BREYANZI for DLBCL?
  • Which are the late-stage emerging therapies under development for the treatment of DLBCL?

Table of Contents

1. Report Introduction

2. BREYANZI Overview in DLBCL

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Regulatory Milestone
  • 2.4. Other Developmental Activities
  • 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. BREYANZI Market Assessment

  • 5.1. Market Outlook of BREYANZI in DLBCL
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of BREYANZI in the 7MM for DLBCL
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of BREYANZI in the United States for DLBCL
    • 5.3.2. Market Size of BREYANZI in Germany for DLBCL
    • 5.3.3. Market Size of BREYANZI in France for DLBCL
    • 5.3.4. Market Size of BREYANZI in Italy for DLBCL
    • 5.3.5. Market Size of BREYANZI in Spain for DLBCL
    • 5.3.6. Market Size of BREYANZI in the United Kingdom for DLBCL
    • 5.3.7. Market Size of BREYANZI in Japan for DLBCL

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options